(Q45127731)

9 December 2017

title

Clinical risk factors for adverse events in allopurinol users (English)

1 reference

9 December 2017

1 reference

Hee Jung Ryu

1

1 reference

9 December 2017

Ran Song

2

1 reference

9 December 2017

Hye Won Kim

3

1 reference

9 December 2017

Jin Hyun Kim

4

1 reference

9 December 2017

Eun Young Lee

5

1 reference

9 December 2017

Yun Jong Lee

6

1 reference

9 December 2017

Yeong Wook Song

7

1 reference

9 December 2017

Eun Bong Lee

8

1 reference

9 December 2017

publication date

1 February 2013

1 reference

The Journal of Clinical Pharmacology

9 December 2017

published in

1 reference

9 December 2017

volume

53

1 reference

9 December 2017

issue

2

1 reference

9 December 2017

page(s)

211-216

1 reference

A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout

9 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270012439715

Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012439715

21 January 2018

Clinical practice. Gout

1 reference

https://api.crossref.org/works/10.1177%2F0091270012439715

Allopurinol hypersensitivity syndrome: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012439715

The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012439715

The Janus faces of allopurinol-allopurinol hypersensitivity syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012439715

Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012439715

Acute renal failure and its risk factors in Stevens-Johnson syndrome and toxic epidermal necrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012439715

Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012439715

Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012439715

Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012439715

HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012439715

HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012439715

A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012439715

The allopurinol hypersensitivity syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012439715

Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012439715

Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012439715

Fatal allopurinol hypersensitivity syndrome after treatment of asymptomatic hyperuricaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012439715

Innate immune recognition: mechanisms and pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012439715

Molecular identification of a danger signal that alerts the immune system to dying cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012439715

Cutting edge: elimination of an endogenous adjuvant reduces the activation of CD8 T lymphocytes to transplanted cells and in an autoimmune diabetes model

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012439715

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012439715

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012439715

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012439715

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012439715

Pleiotropic effects of statin therapy: molecular mechanisms and clinical results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012439715

The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012439715

Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012439715

Relation between adverse events associated with allopurinol and renal function in patients with gout

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012439715

Effect of allopurinol in chronic kidney disease progression and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012439715

Uric acid and incident kidney disease in the community

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012439715

Elevated uric acid increases the risk for kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012439715

21 January 2018

Identifiers

DOI

10.1177/0091270012439715

1 reference

9 December 2017

1 reference